CompletedPhase 2NCT00165477

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
Patrick Y. Wen, MD, MD
Dana-Farber Cancer Institute
Intervention
lenalidomide(drug)
Enrollment
23 enrolled
Eligibility
18 years · All sexes
Timeline
2005 – 2009

Study locations (4)

Collaborators

Celgene Corporation · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Massachusetts General Hospital · University of Virginia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00165477 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma →

← Back to all trials